Flagship explainer
What drives NEKTAR THERAPEUTICS’s return on equity?
ROE is five filed business factors multiplied together.
| Input | Value | Fiscal year | Source |
|---|---|---|---|
| −$164M | FY2025 |
| |
| Income before tax | −$164M | FY2025 |
|
| Operating income | −$140M | FY2025 |
|
| $55.2M | FY2025 |
| |
| Ending assets | $280M | FY2025 |
|
| Beginning assets | $304M | FY2024 |
|
| $89.8M | FY2025 |
| |
| $60.7M | FY2024 |
|
Source:
- SEC filingFiling detailsAccession 0000950170-25-039389
- SEC filingFiling detailsAccession 0001193125-26-104547